The 129 CN-AML patients were further divided into subgroups by the presence of FLT3-ITD and mutation status of NPM1 and CEBPA. Levels of MAP7 expression were compared among different subgroups (GEO accession number GSE6891) (Fig. 1C). This evidence concerns the gene NPM1 and acute myeloid leukemia.